



"SAPPHIRE II is designed to be a simple, definitive eye test for early detection of Alzheimer's."

## Cognoptix eye test designed to identify early-stage Alzheimer's Disease is expected to be available by 2016

"This simple SAPPHIRE eye test has the potential to change the way that Alzheimer's disease is detected and managed," says Carl Sadowsky, MD, FAAN, Medical Director, Premiere Research Institute, West Palm Beach, Fla., and a principal investigator in both the feasibility, pre-pivotal and pivotal clinical trials of the SAPPHIRE eye test.

### LEADERSHIP TEAM

Daniel Vlock, MD  
CEO

Thomas Trometer  
Chief Financial Officer

Charles Kerbage, PhD, MBA  
Director of R & D

### CLINICAL ADVISORS

P. Murali Doraiswamy, MD  
Chief, Division of Biological Psychiatry, Ctr for Study of Aging, Duke University Medical Center

Carl H. Sadowsky, MD  
Director of Research, Premiere Research Institute

Pierre N. Tariot, MD  
Director, Banner Alzheimer's Institute

Gordon Wilcock  
Professor of Clinical Geratology, University of Oxford

Barry D. Greenberg, PhD  
Director, Neuroscience Drug Discovery and Development

### BOARD OF DIRECTORS

Gunnar Weikert, M.D., Ph.D.  
Chairman  
Chairman, Inventages Venture Capital

Christine de los Reyes, Ph.D.  
Vice President, Business Development and Strategic Planning, Alopexx Enterprises

Richard Gill, MD  
President & CEO of TruTouch Technologies, Inc.

### INVESTORS

Inventages Venture Capital  
London, England

Alopexx Enterprises LLC  
Concord, Mass.

Launchpad Ventures  
Boston, Mass.

### PARTNERS

Brigham and Women's Hospital  
Boston, Mass.

Massachusetts General Hospital  
Boston, Mass.

University of California  
San Diego, Calif.

- Cognoptix has developed an in-office, drug/device diagnostic system as an aid in the early detection of Alzheimer's Disease (AD). The SAPPHIRE II eye test designed to identify Alzheimer's Disease (AD) patients via a beta-amyloid (A- beta) signature in their eyes. Significantly faster and an order of magnitude less expensive than PET brain imaging, the test and diagnosis are designed to be quickly completed in any physician's office, including general practitioners. On 09/30/14 Cognoptix announced that it closed the first tranche of a Series D round of financing totaling over \$15 million. The round was co-lead by new investor Alopexx Enterprises and existing investor Inventages, with participation from original investor, Launchpad Venture Group.
- Cognoptix has a strong and comprehensive patent portfolio covering diagnosis of beta amyloid-based diseases via ophthalmic imaging. The patent portfolio includes issued "method" and "device" patents, as well as pending "composition of matter" patents. Exclusive licenses have been acquired from Massachusetts General Hospital (Boston), Brigham and Women's Hospital (Boston), and University of California San Diego.
- There are more than 100 new Alzheimer's drugs that are in various stages of research and development. The ability of the Cognoptix drug/device combination to easily identify and qualify patients for clinical study inclusion, as well as accurately and inexpensively track patient disease progression, can provide pharmaceutical companies with a significant competitive advantage in securing new Alzheimer's drug approvals and differentiating pharmaceutical product performance attributes in Phase 4 studies.

#### SIGNIFICANT COMPETITIVE ADVANTAGES

- SAPPHIRE II is a Class I laser optical device: safe for the eyes, and no exposure limits;
- Proprietary ophthalmic ointment contains aftobetin HCl that selectively binds to beta-amyloid in the lens of the eye;
- First indication is to utilize the system as an aid in the diagnosis of probable Alzheimer's Disease in cases of subjects suspect of having the disease;
- Pre-pivotal study results showed 85% sensitivity and 95% specificity;
- By comparison, clinical diagnosis was predicted by PET amyloid with only 80% sensitivity and 80% specificity.



The Cognoptix SAPPHIRE II system (above) consists of a laser-based reading device and consumable ophthalmic ointment. The eye exam can be given by a general practitioner.